Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,283 | 4 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $3,283 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $451.00 | 1 | Eli Lilly and Company ($451.00) |
| 2018 | $150.00 | 1 | Eli Lilly and Company ($150.00) |
| 2017 | $2,682 | 2 | Eli Lilly and Company ($2,682) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/01/2022 | Eli Lilly and Company | — | — | In-kind items and services | $451.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 01/15/2018 | Eli Lilly and Company | — | — | In-kind items and services | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | ||||||
| 03/28/2017 | Eli Lilly and Company | — | — | In-kind items and services | $1,776.45 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | ||||||
| 01/13/2017 | Eli Lilly and Company | — | — | In-kind items and services | $906.02 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | Eli Lilly and Company | $1,776 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $1,056 | 2 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $451.00 | 1 |
About Dr. Larry Reed, M.D
Dr. Larry Reed, M.D is a Diagnostic Radiology healthcare provider based in Jerseyville, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093775629.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Larry Reed, M.D has received a total of $3,283 in payments from pharmaceutical and medical device companies, with $451.00 received in 2022. These payments were reported across 4 transactions from 1 company. The most common payment nature is "" ($3,283).
Practice Information
- Specialty Diagnostic Radiology
- Other Specialties Diagnostic Radiology
- Location Jerseyville, IL
- Active Since 03/27/2006
- Last Updated 04/20/2016
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1093775629
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.